Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2005;45:18-20
Published online before print November 22, 2004, doi: 10.1161/01.HYP.0000150785.39055.e8
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
45/1/18    most recent
01.HYP.0000150785.39055.e8v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Johnson, R. J.
Right arrow Articles by Kang, D.-H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Johnson, R. J.
Right arrow Articles by Kang, D.-H.
Related Collections
Right arrow Clinical Studies

(Hypertension. 2005;45:18.)
© 2005 American Heart Association, Inc.


Editorial Commentaries

Resurrection of Uric Acid as a Causal Risk Factor in Essential Hypertension

Richard J. Johnson; Dan I. Feig; Jaime Herrera-Acosta; Duk-Hee Kang

From the Division of Nephrology (R.J.J.), Hypertension and Transplantation, University of Florida, Gainesville; Texas Children’s Hospital, (D.I.F.) Baylor College of Medicine, Houston; Instituto de Cardiologia (J.H.-A.), Mexico City, Mexico; and Division of Nephrology (D.-H.K.), Ewha University College of Medicine, Seoul, Korea.

Correspondence to Richard J. Johnson, Division of Nephrology, Hypertension, and Transplantation, PO Box 100024, University of Florida, Gainesville FL 32610. johnsrj@medicine.ufl.edu


An extract of the first 250 words of the full text is provided, because this article has no abstract.
 

In his landmark paper describing the entity of essential hypertension, Frederick Akbar Mahomed observed that many hypertensive subjects came from gouty families, leading him to suggest uric acid as a causal factor in the blood pressure response.1 Ten years later this hypothesis was championed by Haig, who proposed low purine diets as a means to prevent hypertension and vascular disease.2 During the same period the French academician, Henri Huchard, noted that renal arteriolosclerosis (the histological lesion of hypertension) was primarily observed in 3 groups: those with gout or lead poisoning or those with a diet enriched in fatty meat, all conditions associated with hyperuricemia.3

During the early 1900s there continued to be reports linking uric acid with hypertension.4 In the 1960s and 1970s, at a time when hyperuricemia was present in {approx}5% of the US population,5 an elevated uric acid level was observed in 40% to 60% of hypertensive subjects6; similarly, hypertension was observed in 50% to 65% of subjects with gout.7 Cannon et al reported that hyperuricemia was observed in 25% of untreated hypertensive subjects, 50% of those on treatment, and 75% to 100% of those with malignant hypertension or renal dysfunction.8 Population-based studies also found an increased frequency of hypertension with stepwise increases in serum uric acid levels in both blacks and whites.9

Whereas these studies confirmed initial impressions of a close association of uric acid with hypertension, the studies did not address causality. Indeed, most authorities proposed that the presence of hyperuricemia in the hypertensive subject . . . [Full Text of this Article]




This article has been cited by other articles:


Home page
Clin. Chem.Home page
W. Zhang, K. Sun, Y. Yang, H. Zhang, F. B. Hu, and R. Hui
Plasma Uric Acid and Hypertension in a Chinese Community: Prospective Study and Metaanalysis
Clin. Chem., November 1, 2009; 55(11): 2026 - 2034.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
J. P. Forman, H. Choi, and G. C. Curhan
Uric Acid and Insulin Sensitivity and Risk of Incident Hypertension
Arch Intern Med, January 26, 2009; 169(2): 155 - 162.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
A. Dehghan, M. van Hoek, E. J.G. Sijbrands, A. Hofman, and J. C.M. Witteman
High Serum Uric Acid as a Novel Risk Factor for Type 2 Diabetes
Diabetes Care, February 1, 2008; 31(2): 361 - 362.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
S. D. Nath, V. S. Voruganti, N. H. Arar, F. Thameem, J. C. Lopez-Alvarenga, R. Bauer, J. Blangero, J. W. MacCluer, A. G. Comuzzie, and H. E. Abboud
Genome Scan for Determinants of Serum Uric Acid Variability
J. Am. Soc. Nephrol., December 1, 2007; 18(12): 3156 - 3163.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
X. Gao, L. Qi, N. Qiao, H. K. Choi, G. Curhan, K. L. Tucker, and A. Ascherio
Intake of Added Sugar and Sugar-Sweetened Drink and Serum Uric Acid Concentration in US Men and Women
Hypertension, August 1, 2007; 50(2): 306 - 312.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
L. G. Sanchez-Lozada, E. Tapia, R. Lopez-Molina, T. Nepomuceno, V. Soto, C. Avila-Casado, T. Nakagawa, R. J. Johnson, J. Herrera-Acosta, and M. Franco
Effects of acute and chronic L-arginine treatment in experimental hyperuricemia
Am J Physiol Renal Physiol, April 1, 2007; 292(4): F1238 - F1244.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
T. Nakagawa, W. Sato, O. Glushakova, M. Heinig, T. Clarke, M. Campbell-Thompson, Y. Yuzawa, M. A. Atkinson, R. J. Johnson, and B. Croker
Diabetic Endothelial Nitric Oxide Synthase Knockout Mice Develop Advanced Diabetic Nephropathy
J. Am. Soc. Nephrol., February 1, 2007; 18(2): 539 - 550.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
E. Krishnan, C. K. Kwoh, H. R. Schumacher, and L. Kuller
Hyperuricemia and Incidence of Hypertension Among Men Without Metabolic Syndrome
Hypertension, February 1, 2007; 49(2): 298 - 303.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
A. B. Weder
Evolution and Hypertension
Hypertension, February 1, 2007; 49(2): 260 - 265.
[Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
J. P. Forman, H. Choi, and G. C. Curhan
Plasma Uric Acid Level and Risk for Incident Hypertension Among Men
J. Am. Soc. Nephrol., January 1, 2007; 18(1): 287 - 292.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
T. S. Perlstein, O. Gumieniak, G. H. Williams, D. Sparrow, P. S. Vokonas, M. Gaziano, S. T. Weiss, and A. A. Litonjua
Uric Acid and the Development of Hypertension: The Normative Aging Study
Hypertension, December 1, 2006; 48(6): 1031 - 1036.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
P. B. Mellen, A. J. Bleyer, T. P. Erlinger, G. W. Evans, F. J. Nieto, L. E. Wagenknecht, M. R. Wofford, and D. M. Herrington
Serum Uric Acid Predicts Incident Hypertension in a Biethnic Cohort: The Atherosclerosis Risk in Communities Study
Hypertension, December 1, 2006; 48(6): 1037 - 1042.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
D. I. Feig, B. Rodriguez-Iturbe, T. Nakagawa, and R. J. Johnson
Nephron Number, Uric Acid, and Renal Microvascular Disease in the Pathogenesis of Essential Hypertension
Hypertension, July 1, 2006; 48(1): 25 - 26.
[Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
C. Zoccali, R. Maio, F. Mallamaci, G. Sesti, and F. Perticone
Uric Acid and Endothelial Dysfunction in Essential Hypertension
J. Am. Soc. Nephrol., May 1, 2006; 17(5): 1466 - 1471.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
Y. Iwashima, T. Horio, K. Kamide, H. Rakugi, T. Ogihara, and Y. Kawano
Uric Acid, Left Ventricular Mass Index, and Risk of Cardiovascular Disease in Essential Hypertension
Hypertension, February 1, 2006; 47(2): 195 - 202.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
K. Masuo, T. Katsuya, Y. Fu, H. Rakugi, T. Ogihara, and M. L. Tuck
Lys418Asn Polymorphism of the {alpha}2-Adrenoceptor Gene Relates to Serum Uric Acid Levels But Not to Insulin Sensitivity
Hypertension, July 1, 2005; 46(1): 144 - 150.
[Abstract] [Full Text] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
J. L Reid
Review: Molecular-specific effects of angiotensin II antagonists: clinical relevance to treating hypertension?
Journal of Renin-Angiotensin-Aldosterone System, March 1, 2005; 6(1): 15 - 24.
[Abstract] [PDF]